Neurocrine Biosciences
NBIX
#1366
Rank
HK$120.70 B
Marketcap
HK$1,211
Share price
0.84%
Change (1 day)
21.43%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2025 (TTM): HK$4.54 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are HK$2.68 Billion. In 2024 the company made an earning of HK$4.76 Billion, an increase over its 2023 earnings that were of HK$2.42 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) HK$4.54 B-4.69%
2024 HK$4.76 B96.41%
2023 HK$2.42 B41.13%
2022 HK$1.72 B73.74%
2021 HK$0.99 B-8.82%
2020 HK$1.08 B77.78%
2019 HK$0.61 B49.83%
2018 HK$0.40 B-142.57%
2017 -HK$0.96 Billion-14.73%
2016 -HK$1.13 Billion53.15%
2015 -HK$0.74 Billion46.25%
2014 -HK$0.51 Billion29.66%
2013 -HK$0.39 Billion-3530.8%
2012 HK$11.27 M-95.73%
2011 HK$0.26 B
2009 -HK$0.38 Billion-45.38%
2008 -HK$0.68 Billion-58.87%
2007 -HK$1.66 Billion87.3%
2006 -HK$0.89 Billion351.97%
2005 -HK$0.2 Billion-52.09%
2004 -HK$0.41 Billion-10.98%
2003 -HK$0.46 Billion
2001 -HK$0.35 Billion
1999 -HK$0.16 Billion108.32%
1998 -HK$73.96 Million
1996 HK$22.57 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Repligen
RGEN
HK$0.20 B-95.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
HK$12.31 B 171.24%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
-HK$0.14 Billion-102.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
HK$175.18 B 3,758.64%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
HK$12.92 B 184.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
HK$92.26 B 1,932.24%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
HK$0.39 B-91.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-HK$0.33 Billion-107.16%๐Ÿ‡บ๐Ÿ‡ธ USA